Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Thyroid cancer

Lenvatinib — beyond trials

Nature Reviews Endocrinology volume 13, page 688 (2017)Cite this article

Subjects

Access through your institution
Buy or subscribe

The study included 75 patients with radioiodine-refractory differentiated thyroid cancer (rDTC) who were treated at 27 centres across France. Patients were treated for a median of 6 months, receiving a median dose of lenvatinib of 20 mg per day. The median follow-up period was 7 months from initiation of lenvatinib treatment.

CT scans were used for morphological examinations. No complete response was observed, but 23 patients had a partial response, 38 had stable disease and 4 had progressive disease. Some patients also reported improvements in DTC-related symptoms. Survival at 6 months and 12 months was 89% and 79%, respectively. In addition, the median progression-free survival was 10 months.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Berdelou, A. et al. Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice. Thyroid http://dx.doi.org/10.1089/thy.2017.0205 (2017)

Download references

Authors
  1. Claire Greenhill
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Web links

Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Greenhill, C. Lenvatinib — beyond trials. Nat Rev Endocrinol 13, 688 (2017). https://doi.org/10.1038/nrendo.2017.149

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrendo.2017.149

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing